菌群触发型前体药物在结肠靶向治疗中的研究进展  

Research Development of Prodrugs Triggered by Colon Bacteria-Releasing Enzymes on Colon-Targeted Treatment

作　　者：梁建娣[1] 宋三孔[1] 王晓飞[1] 

机构地区：[1]兰州大学第二医院药学部,兰州730030

出　　处：《中国药学杂志》2015年第1期1-6,共6页Chinese Pharmaceutical Journal

基　　金：中央高校基本科研业务专项基金项目(lzujbky-2013-46)

摘　　要：通过查阅国内外相关文献,对目前菌群触发型前体药物的制备原理、释药机制、存在问题等进行归纳总结。与普通的药物相比,菌群触发型前体药物经结肠细菌特异性酶的降解,能在结肠靶向释药,起到治疗作用。菌群触发型前体药物具有特异性、精准性等释药特点,能提高结肠靶向治疗作用,降低药物不良反应,具有良好的应用前景。By researching the relevant papers at home and abroad, the the principles of preparation, drug release mechanism, existing problems and so on were analysed and summarized on prodrugs triggered by colon bacteria-releasing enzymes （PTCBE）. Compared with ordinary drugs, PTCBE was degraded by colon bacteria-releasing enzymes on colon-targeted treatment. PTCBE have the drug release characters of specificity, accuracy and so on for the colon-targeted treatment and can reduce the adverse drug reactions. Thus PTCBE have the good prospects of applications.

关 键 词：菌群触发型 前体药物 结肠靶向 

分 类 号：R944[医药卫生—药剂学]